PRESORTEDFIRST CLASSU.S.POSTAGE

PAIDASBURY PARK,NJ

PERMIT NO.24

©2002 Abbott Laboratories • xxx-xxx-xxxx-x • July 2002 • Printed in USA

FP

O

www.abbottimmunology.com

People with debilitating immunological diseases need answers.That’s why Abbott Immunology is dedicated to providinganswers for them and the health care professionals who treatthem—answers which use leading-edge technology to target thecauses of human diseases, with more aggressive treatment options,and which one day may lead us to a cure.

Introducing Abbott Immunology

In our quest to discover answers quickly, we have brought together leading-edge biotechnology with the experience and resources of one of the world’s largest and most respected pharmaceutical companies.

This combination has produced an innovative approach to rapidly developing therapies that target the specific causes of diseases, utilizing the latest molecular technologies to produce fully human antibodies against critical mediators of disease processes like TNF-α and IL-12.

These human proteins play key roles in the inflammatory response underlyingsuch immunological diseases as rheumatoid arthritis and Crohn’s disease. Several of these promising compounds are currently in clinical trials.

Abbott Immunology is equally dedicated to the discovery of innovative small-molecule drugs as orally deliverable targeted therapies, including:■ Novel compounds that block the action of certain pro-inflammatory cytokines

■ Novel immunosuppressive agents that inhibit critical signal transduction pathways in immune cells

■ Novel anti-angiogenic compounds that block the signal transduction of key mediators in pathological new blood vessel formation at sites of inflammation

An Innovative Approach to Discovery

1i

The goal of our targeted therapies is to give to people with immunologicaldiseases and the health care professionalswho treat them, new hope through more aggressive treatment options. Thediscovery efforts of Abbott Immunologyare focused on improving the ability ofhealth care professionals to treat a widearray of these conditions, including:

At the heart of Abbott Immunology is the Abbott Bioresearch Center in Worcester, Massachusetts. Abbott Bioresearch Center is a cutting-edge discovery research and production unit, founded in 1989, committed to finding new treatments for autoimmune diseases and new ways to help prevent transplant rejection. This 370,000-square-foot center also houses a multiproduct biologics production facility with employees and capabilitiesready to meet the needs of health care professionals and patients around the world.

■ Rheumatoid arthritis

■ Crohn’s disease

■ Multiple sclerosis

■ Psoriasis

■ Sepsis

■ Systemic lupus erythematosus

■ Transplant rejection

Focused on Targeted Therapies

Inside the Abbott Bioresearch Center

2 3

4 5

Employing Leading-Edge Technologies inResearch, Discovery, and Manufacturing

■ Proprietary antibody display technology: a rapid, innovative way to create optimized fully human antibodies against target antigens such as TNF-α and IL-12, based on a collaboration with Cambridge Antibody Technology

■ Mammalian cell expression systems to efficiently produce fully human monoclonal antibodies, with experience in yeast and bacterial production of other therapeutic proteins

■ Proprietary technology platform to discover novel small-molecule inhibitors of protein kinases,the class of enzymes which regulate most signal transduction pathways in human cells

■ Large-scale production technology for fully human antibodies and other therapeutic proteins from clinical trial supply throughcommercial product launch